Colon cancer treatment doesn’t have to be hit or miss.
In this episode of Outsmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, explains why most colon cancer treatments fail to deliver lasting results — and how deep precision mapping changes everything. Using DNA and RNA sequencing, spatial biology, and immune profiling, his team identifies thousands of data points to design treatments tailored to each patient’s unique tumor biology.
Dr. Prato breaks down how this advanced approach turns “cold” tumors — which resist standard therapies — into “hot” immune-responsive targets. By combining precision-tested medications, microdosed chemotherapy, and immune cell therapies like natural killer (NK) and dendritic cell activation, Envita helps patients achieve stronger responses with fewer side effects.

🎯 What You’ll Learn in This Episode:

• Why standard colon cancer care often fails
• The difference between DNA, RNA, and immune mapping
• How deep sequencing and custom drug design personalize therapy
• What “cold” and “hot” tumors mean for your immune system
• How microdosed chemo and immune targeting work together
• The 35x better responses and 43x better quality of life seen in published results*

*(See Outcomes Disclaimer Below)
📍 Envita Medical Centers – Scottsdale, AZ
🌐 Learn more: https://www.envita.com
📞 Speak to a care coordinator: 866-830-4576
“Don’t fight colon cancer blindly — use data to target and defeat it.”

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at:

https://www.scirp.org/journal/paperinformation?paperid=132493